A Novel Evaluation of Current Psychiatric Treatment Paradigms Involving Polypharmacy via Resting-State Functional Magnetic Resonance Imaging (fMRI) in a Sample of Patients With Bipolar I Disorder
ISEF · 2022 Behavioral and Social Sciences Third Award
Overview
As bipolar I disorder (BD-I) is characterized by manic, mixed, and depressive episodes, polypharmacy—combining 2 or more medications simultaneously—is common for BD-I psychiatric treatment to address these wide-ranging symptoms. However, high treatment inadequacy rates for BD-I demonstrate a flaw in the current symptom and diagnosis-based treatment paradigm. This study’s purpose was to use resting-state functional magnetic resonance imaging to comprehensively examine the neuroscientific validity of 2 polypharmacies typically used in BD-I. Anatomical & functional images, and patient medication history & diagnoses, were obtained from the OpenfMRI database’s UCLA CNP Study. 32 BD-I patients were separated into 2 groups based on their prescribed polypharmacy: either a second-generation antipsychotic (SGA) with a mood stabilizer (MS), or an SGA with an anxiolytic benzodiazepine (AB). Since AB’s affect GABA pathways in the hippocampus and MS’s affect glutamate pathways in the ventral striatum, these were selected as the 2 regions of interest (ROIs). Preprocessing and analyses were performed using FSL. Following first-level analysis, group-level analysis was performed to compare resting-state BOLD signals in the ventral striatum and hippocampus between experimental groups. Analyses showed no significant differences in BOLD activation between groups in either ROI, revealing that these 2 regimens don’t act as direct combinations of the individual medications they’re composed of. These findings highlight the current limitations of polypharmacy in accounting for unique neurological differences and stress the need for further integration between neuroscience and psychiatry’s clinical applications to develop a more precise and individually-optimized psychiatric treatment paradigm.
Awards (1)
- Third Award of $1,000 $1,000
Competition history
- ISEF 2022
Resources
Related projects
ISEF · 2026
A Multi-Omics and Machine Learning Approach for Identifying Potential Salivary Biomarkers of and Treating Major Depressive Disorder
ISEF · 2014
Cognitive Performance in Schizophrenia & Bipolar Disorder & their First-Degree Relatives
ISEF · 2019
The Development of a Novel Prediction Model for Bipolar-I Disorder Utilizing Radiomic Analysis
ISEF · 2025
Harmony Plus: A User-Adaptive System for Neurocognitive Rehabilitation With Genetic Personalization and Real-Time Cognitive Load Monitoring in Bipolar Disorder
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair